"Designing Growth Strategies is in our DNA"

U.S. Autism Spectrum Disorder Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Therapy (Antipsychotic Drugs, SSRIs/Antidepressants, Stimulants, Sleep Medications, and Others), By Disease (Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, and Others), By Age Group (Children and Adults), By Distribution Channel (Hospital Pharmacies, Drugs Stores & Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2023-2030

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI108931

 


To get information on various segments, share your queries with us

ATTRIBUTE

DETAILS

Study Period

2019-2030

Base Year

2022

Estimated Year

2023

Forecast Period

2023-2030

Historical Period

2019-2021

Growth Rate

CAGR of 8.7% from 2023 to 2030

Unit

Value (USD Billion)

Segmentation

 

By Drug Therapy

  • Antipsychotic Drugs
  • SSRIs/Antidepressants
  • Stimulants
  • Sleep Medications
  • Others

By Disease

  • Autistic Disorder
  • Asperger Syndrome
  • Pervasive Developmental Disorder (PDD)
  • Others

By Age Group

  • Children
  • Adults

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
  • 2019-2030
  • 2022
  • 2019-2021
  • 80
Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann